open access

Vol 62, No 1 (2011)
Original papers
Published online: 2011-03-01
Submitted: 2013-02-15
Get Citation

Alendronate 70 therapy in elderly women with post-menopausal osteoporosis: the problem of compliance

Ewa Sewerynek, Bogdan Małkowski, Ewa Karzewnik, Wioletta Stepien-Klos, Maria Tabaszewska, Marek Lasota, Grażyna Krupińska, Anna Glądalska, Wanda Horst-Sikorska, Michał Stuss
Endokrynologia Polska 2011;62(1):24-32.

open access

Vol 62, No 1 (2011)
Original papers
Published online: 2011-03-01
Submitted: 2013-02-15

Abstract


Introduction: More than half of those with chronic diseases, including osteoporosis, discontinue treatment during the first year of its administration. This problem increases over the course of continued follow-up. Additionally, it has been observed that 13% of women, prescribed oral daily alendronate, do not even start the treatment, while 20% of patients discontinue the therapy during the first four months. On the other hand, those patients who are compliant achieve increased bone mass density with a simultaneous decrease of fracture risk. The aim of our study was to assess the adherence to the recommended alendronate 70 administration protocol over the course of 12 months by women with post-menopausal osteoporosis.
Material and methods: Adherence (compliance plus persistence) to alendronate 70 therapy was assessed in a prospective study of 153 post-menopausal women, followed up for one year with monitoring every two months.
Results: Adherence to therapy of all the study participants was high during the entire study period, the patients remaining compliant after a year in 95.08 ± 1.39% (mean ± SEM) of cases, and the mean persistence with medication was 347.05 ± 5.07 days. In the group of patients who interrupted treatment, the mean persistence was 212.44 days. One of the study participants did not start the treatment, and another two discontinued the therapy within 30-60 days of the study onset (between the first two visits). Facilitated contacts with the doctor, continuous access to prescribed treatment and frequent visits significantly improved patient compliance. The common reason for discontinuation was side effects, while age (but not education) affected the rate of compliance with therapy. The worst results were obtained in the group of patients with osteoporosis diagnosed more than five years before the study, particularly in the subgroup where alendronate was being used for the first time or where treatment resumed after a substantial break.
Conclusions: The obtained results indicate that better adherence to alendronate 70 therapy, administered once a week, depends on more frequent monitoring of treated patients. (Pol J Endocrinol 2011; 62 (1): 24-29)

Abstract


Introduction: More than half of those with chronic diseases, including osteoporosis, discontinue treatment during the first year of its administration. This problem increases over the course of continued follow-up. Additionally, it has been observed that 13% of women, prescribed oral daily alendronate, do not even start the treatment, while 20% of patients discontinue the therapy during the first four months. On the other hand, those patients who are compliant achieve increased bone mass density with a simultaneous decrease of fracture risk. The aim of our study was to assess the adherence to the recommended alendronate 70 administration protocol over the course of 12 months by women with post-menopausal osteoporosis.
Material and methods: Adherence (compliance plus persistence) to alendronate 70 therapy was assessed in a prospective study of 153 post-menopausal women, followed up for one year with monitoring every two months.
Results: Adherence to therapy of all the study participants was high during the entire study period, the patients remaining compliant after a year in 95.08 ± 1.39% (mean ± SEM) of cases, and the mean persistence with medication was 347.05 ± 5.07 days. In the group of patients who interrupted treatment, the mean persistence was 212.44 days. One of the study participants did not start the treatment, and another two discontinued the therapy within 30-60 days of the study onset (between the first two visits). Facilitated contacts with the doctor, continuous access to prescribed treatment and frequent visits significantly improved patient compliance. The common reason for discontinuation was side effects, while age (but not education) affected the rate of compliance with therapy. The worst results were obtained in the group of patients with osteoporosis diagnosed more than five years before the study, particularly in the subgroup where alendronate was being used for the first time or where treatment resumed after a substantial break.
Conclusions: The obtained results indicate that better adherence to alendronate 70 therapy, administered once a week, depends on more frequent monitoring of treated patients. (Pol J Endocrinol 2011; 62 (1): 24-29)
Get Citation

Keywords

osteoporosis; compliance; persistence; alendronate 70; reasons for therapy discontinuation

About this article
Title

Alendronate 70 therapy in elderly women with post-menopausal osteoporosis: the problem of compliance

Journal

Endokrynologia Polska

Issue

Vol 62, No 1 (2011)

Pages

24-32

Published online

2011-03-01

Bibliographic record

Endokrynologia Polska 2011;62(1):24-32.

Keywords

osteoporosis
compliance
persistence
alendronate 70
reasons for therapy discontinuation

Authors

Ewa Sewerynek
Bogdan Małkowski
Ewa Karzewnik
Wioletta Stepien-Klos
Maria Tabaszewska
Marek Lasota
Grażyna Krupińska
Anna Glądalska
Wanda Horst-Sikorska
Michał Stuss

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl